{"protocolSection":{"identificationModule":{"nctId":"NCT02793687","orgStudyIdInfo":{"id":"2013-08-11"},"organization":{"fullName":"Pharmasoft","class":"INDUSTRY"},"briefTitle":"Study of Efficacy and Safety of MEXIDOL®","officialTitle":"Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety of the Drug MEXIDOL® for a Long Sequence of Therapy in Patients With Hemispheric Ischemic Stroke in the Acute and Early Recovery Period"},"statusModule":{"statusVerifiedDate":"2016-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-10"},"primaryCompletionDateStruct":{"date":"2016-05","type":"ACTUAL"},"studyFirstSubmitDate":"2016-05-31","studyFirstSubmitQcDate":"2016-06-03","studyFirstPostDateStruct":{"date":"2016-06-08","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-06-03","lastUpdatePostDateStruct":{"date":"2016-06-08","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pharmasoft","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"A multicenter, prospective, randomized, double-blind, placebo-controlled, parallel group study in patients with stroke"},"conditionsModule":{"conditions":["Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":150,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Mexidol","type":"EXPERIMENTAL","description":"Sequential therapy with MEXIDOL® as follows: MEXIDOL® (i.v. solution) - 500 mg / day. for 10 days, followed by application MEXIDOL® 1 tablet of 125 mg three times a day (daily dose 375 mg) for 8 weeks.\n\nThe use of the study drug is held with basic therapy.","interventionNames":["Drug: MEXIDOL® (ethylmethylhydroxypyridine succinate)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Sequential therapy as follows: Placebo (i.v. solution) for 10 days followed by placebo 1 tablet three times a day for 8 weeks.\n\nThe use of a placebo is held with basic therapy.","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"MEXIDOL® (ethylmethylhydroxypyridine succinate)","armGroupLabels":["Mexidol"]},{"type":"OTHER","name":"Placebo","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"modified Rankin Scale","timeFrame":"5 times during 67-71 days of the treatment"}],"secondaryOutcomes":[{"measure":"The National Institutes of Health Stroke Scale","timeFrame":"5 times during 67-71 days of the treatment"},{"measure":"Barthel Index","timeFrame":"5 times during 67-71 days of the treatment"},{"measure":"Beck Depression Inventory","timeFrame":"5 times during 67-71 days of the treatment"},{"measure":"EuroQoL Quality of Life Scale","timeFrame":"5 times during 67-71 days of the treatment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Diagnosis: hemispheric ischemic stroke (codes ICD-10: I63.0 - I63.9), primary.\n2. Patients of both sexes, from 40 to 80 years.\n3. Patients who are able to understand the purpose of this study and observe the requirements of the Protocol;\n4. The time from onset of stroke - not more than 72 hours.\n5. Based on the Rankin Scale score of 3 points or more at the time of enrollment.\n6. Evaluation of NIHSS scale from 5 to 15 points.\n7. Based on the depression scale Beck \\<19 points\n8. Have personally signed and dated by the patient (or otherwise disinterested witness who is not a member of the research team and is not in direct subordinate to the principal investigator, in the absence of physical possibility of signing the patient) informed consent form.\n9. Have a negative pregnancy test for women of childbearing age.\n10. Consent to use adequate contraception female patients and / or willingness to use contraception female partners of male patients or abstinence from sexual activity for the period of the study.\n\nExclusion Criteria:\n\n1. Lack of diagnosis: hemispheric ischemic stroke (codes ICD-10: I63.0 - I63.9), primary.\n2. Age \\<40 and\\> 80 years.\n3. Assessment of the scale NIHSS \\<5 or\\> 15 points\n4. Hemorrhagic stroke (confirmed with imaging techniques (CT or MRI).\n5. Hemorrhagic infarction (ischemic stroke with hemorrhagic impregnation).\n6. Repeated ischemic stroke.\n7. Parkinson's disease.\n8. Epilepsy.\n9. Demyelinating disease of the nervous system.\n10. hereditary degenerative diseases of the CNS.\n11. The presence of CNS infectious diseases in history.\n12. Traumatic brain injury with severe neurological symptoms and cognitive disorders (including history).\n13. Unstable angina pectoris.\n14. Myocardial infarction, prescription of less than 3 months.\n15. Chronic heart failure functional class IV according to the classification of the New York Heart Association (NYHA).\n16. atrioventricular block degree II-III.\n17. Systemic connective tissue diseases.\n18. Chronic obstructive pulmonary stage III-IV disease.\n19. Acute surgical pathology.\n20. Heavy, decompensated heart disease, liver, kidney, acute / chronic renal / hepatic failure.\n21. A history of cancer, immunosuppressive conditions, tuberculosis, drug or alcohol addiction, mental illness.\n22. A history of any material, according to a research physician, state, prevents the inclusion in the study.\n23. Acute infectious diseases (influenza, SARS, etc.) In less than 4 weeks before the start of the study.\n24. Availability of information on lactose intolerance / congenital galactose intolerance; Lapp lactase deficiency or glucose-galactose syndrome malabsorption.\n25. Pregnancy, lactation.\n26. Mental, physical or other reasons that do not allow to adequately assess their behavior and comply with the terms of the protocol correctly.\n27. Patients who are employees of the research center, the sponsoring company, as well as their family members.\n28. Participation in a clinical trial of drugs in less than 3 months prior to the study.\n29. Any other conditions and circumstances make it difficult, according to the researcher, participated in the study.\n30. Individual intolerance emoxypine, as well as preparations containing a salt of succinic acid and vitamin B6 in history.\n31. The presence of any contraindications to the use of the drug MEXIDOL®\n32. No personally signed and dated by the patient (or otherwise disinterested witness in the absence of physical possibility of signing the patient) informed consent form.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]}},"annotationSection":{"annotationModule":{"unpostedAnnotation":{"unpostedResponsibleParty":"Pharmasoft","unpostedEvents":[{"type":"RELEASE","date":"2021-03-10"},{"type":"RESET","date":"2021-04-05"}]}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","submissionTracking":{"estimatedResultsFirstSubmitDate":"2021-03-10","submissionInfos":[{"releaseDate":"2021-03-10","resetDate":"2021-04-05"}]}},"conditionBrowseModule":{"meshes":[{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000070020","term":"Emoxypine succinate"}],"ancestors":[{"id":"D000000975","term":"Antioxidants"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000011619","term":"Psychotropic Drugs"}],"browseLeaves":[{"id":"M21550","name":"Pharmaceutical Solutions","relevance":"LOW"},{"id":"M249902","name":"Emoxypine succinate","asFound":"Ascorbic acid 500 mg","relevance":"HIGH"},{"id":"M3982","name":"Antioxidants","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M14164","name":"Psychotropic Drugs","relevance":"LOW"}],"browseBranches":[{"abbrev":"PhSol","name":"Pharmaceutical Solutions"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"PsychDr","name":"Psychotropic Drugs"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"}]}},"hasResults":false}